Biotechnology · Healthcare
Board Member
2024-10-11–present
Board Member
Damora Therapeutics, Inc. (DMRA)Equibles does not estimate personal net worth.
Get an email with a short summary when Damora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DMRA alertsAmy Wechsler is recorded as Board Member at Damora Therapeutics, Inc. (DMRA) since October 11, 2024. Damora Therapeutics, Inc. reported in an 8-K filed November 10, 2025 that Amy Wechsler resigned as Board, effective November 10, 2025. The same filing states: “The resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.” Damora Therapeutics, Inc. reported in an 8-K filed October 15, 2024 that Amy Wechsler was appointed Class I director, effective October 11, 2024. Damora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Damora Therapeutics, Inc. includes Jennifer Jarrett (CEO and Board Member), Sherwin Sattarzadeh (CEO and COO), Peter Harwin (Chairman and Board Member) and 7 others.
“Anne Prener, M.D., David Shapiro, M.D. and Amy Wechsler M.D. resigned from the Board and any respective committee of the Board to which they were members.”
“The resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
“On October 15, 2024, the Board of Directors (the “Board”) of Galecto, Inc. (the “Company”), increased its size to seven directors and appointed Amy Wechsler to join the Board, effective as of October 11, 2024.”
2024-10-11–present
2024-10-11–2025-11-10
Biotechnology · Healthcare
Board Member
2024-10-11–present
“The resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Damora Therapeutics, Inc. (DMRA)